Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Lim CT, Kola B, Korbonits M
Analyses from a phase II basket trial highlighted the potential role of T-DM1 in HER2 -mutant NSCLC patients, administered at the dose of 3.6 mg/kg intravenously every 3 weeks (Q3W)
For isolation of cardiac subregions, hearts were rinsed in PBS and a cannula passed through the aorta into the left ventricle
Diabetes & Endocrinology, 7(9), 715725
Update on the management of diabetic retinopathy: anti-VEGF agents for the prevention of complications and progression of nonproliferative and proliferative retinopathy
US$ 23.10
US$ 25.70
US$ 25.79
US$ 20.69
US$ 20.16
US$ 21.37
US$ 29.14
US$ 29.19
